Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) recently announced that its 80% owned subsidiary, Cannevert Therapeutics Ltd. (“CTL”), signed a letter of intent with the Fundación de Investigación (“FDI”) in San Juan, Puerto Rico, to conduct the first human study of CTL-X for the treatment of pain. The study of CTL-X, CTL’s lead cannabis strain for pain, will be conducted in two stages to assess the treatment’s analgesic effects. “We are pleased to see Cannevert’s lead strain for pain is finally heading into human trials. It’s important to us to move quickly into this next phase of providing clinical proof of cannabis’ effectiveness, this after our chemical and animal assays delivered favorable results,” Veritas CEO Lui Franciosi stated in the news release.
To view the full press release, visit http://dtn.fm/Ih7Hp
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment